Coronavirus (Covid-19)
A collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
Pemivibart, a monoclonal antibody for preexposure prophylaxis for SARS-CoV-2, was recently authorized for emergency use by the FDA. The immunobridging data on which this EUA is based are presented.
SARS-CoV-2 continues to evolve under immunologic pressure. A synthesized version of pemivibart, an anti–SARS-CoV-2 monoclonal antibody with recent emergency-use authorization, showed mixed activity against emerging variants.
SARS-CoV-2 infection leads to postacute sequelae in many organ systems. In this study, the risk of postacute sequelae decreased over time but remained substantial even among vaccinated persons infected in the omicron era.
Members of the National Academies of Sciences, Engineering, and Medicine describe the process and rationale for the development of the 2024 definition of persistent Covid-19 symptoms (long Covid).
The millions of people worldwide who are suffering from a vast array of disabling symptoms long after being infected with SARS-CoV-2 may eventually benefit from a new consensus definition of long Covid.
Recognizing that public health crises often hit hardest in underresourced communities, two academic medical centers have partnered with the Chicago Department of Public Health to provide rapid responses to outbreaks.
In this randomized trial, adults who had been exposed to a household contact with Covid-19 were given nirmatrelvir–ritonavir or placebo. Prophylaxis with nirmatrelvir–ritonavir did not prevent symptomatic Covid-19.
The federal government’s initial response to H5N1 avian influenza suggests that elected officials and other key decision makers may not be heeding the lessons from Covid-19.
Public statements about Covid that a Stanford faculty member made in 2020 reinvigorated debate over academic freedom and institutional obligations, particularly in cases where public health is at stake.
A data survey of 1.8 million people in Nebraska showed that XBB.1.5 vaccine effectiveness was 52% against infection and 67% against hospitalization, despite a decline in circulating XBB.1.5 during data collection.
The antibody that mediates the occurrence of VITT associated with adenoviral-based Covid-19 vaccines is nearly identical to the antibodies produced in response to natural adenoviral infection.
In fully vaccinated patients with risk factors for severe disease and patients (vaccinated or unvaccinated) without such risk factors, nirmatrelvir–ritonavir did not significantly shorten the time to alleviation of Covid-19 symptoms.
NEJM Covid-19 Update
HealthMap of the Coronavirus Outbreak
